Reduction of increased intraocular pressure in patients with open-angle glaucoma and increased intraocular pressure. Reduction of increased intraocular pressure in children with increased intraocular pressure and pediatric glaucoma.
active substance: latanoprost
1 ml of the drug contains Latanoprost – 0.05 mg
excipients: benzalkonium chloride, sodium dihydrogen phosphate monohydrate, sodium hydrogen phosphate anhydrous, sodium chloride, purified water.
LATANOX DOSAGE FORM
LATANOX MAIN PHYSICAL AND CHEMICAL PROPERTIES:
colorless transparent liquid.
PLATANOX HARMACOLOGICAL GROUP
Anti-glaucoma drugs and miotics. Latanoprost. ATX code S01E E01.
Research has shown that latanoprost is effective as monotherapy. In addition, clinical studies of the combined use of the drug have been conducted. These included studies that showed latanoprost was effective in combination with beta-blockers (timolol). Short-term (1 or 2 weeks) studies show that the effect of latanoprost is additive when used in combination with adrenergic receptor agonists (dipivalil epinephrine), oral carbonic anhydrase inhibitors (acetazolamide) and at least partially additive when used with cholinergic agonists (pilocarpine).
Clinical studies have shown that latanoprost does not significantly affect the production of intraocular fluid. There was no evidence of any effect of Latanoprost on the hemato-ophthalmologic barrier.
Latanoprost did not cause fluorescein leakage in the posterior segment of human pseudophakic eyes during short-term treatment.
There were no significant pharmacological effects of Latanoprost in clinical doses on the cardiovascular and respiratory systems.
Latanoprost (molecular weight 432.58) is an isopropyl ester of the active substance, that is, prodrugs that are inactive by themselves, but after hydrolysis with the formation of latanoprost acid, it becomes biologically active.
Prodrugs penetrate well through the cornea, and all drugs that enter the intraocular fluid are hydrolyzed when passing through the cornea.
Human studies have shown that the maximum concentration in the intraocular fluid is reached 2:00 after topical application. After topical application in monkeys, latanoprost is distributed mainly in the anterior segment, in the conjunctiva and in the eyelids. Only a small amount of the drug reaches the posterior segment.
In these, there is practically no metabolism of latanoprost acid. The main metabolism of the drug occurs in the liver. In humans, the half-life is 17 minutes.
To reduce increased intraocular pressure in patients with open-angle glaucoma and increased ophthalmotonus.
Individual hypersensitivity to Latanoprost, benzalkonium chloride or other components of the drug.